The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Precision medicine at ASCO GI 2021
Pashtoon M. Kasi, MD, MS, University of Iowa, Iowa City, IA, discusses precision medicine updates presented at this years American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium, including the use of targeted therapies in cholangiocarcinoma, as well as maintenance olaparib as evaluated in the POLO study (NCT02184195). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
